Patient-derived organoids for precision cancer immunotherapy

73Citations
Citations of this article
151Readers
Mendeley users who have this article in their library.

Abstract

Cancer immunotherapy has revolutionized the way tumors are treated. Nevertheless, efficient and robust testing platforms are still missing, including clinically relevant human ex vivo tumor assays that allow pretreatment testing of cancer therapies and selection of the most efficient and safe therapy for a specific patient. In the case of immunotherapy, this testing platform would require not only cancer cells, but also the tumor microenvironment, including immune cells. Here, we discuss the applications of patient-derived tumor organoid cultures and the possibilities in using complex immune-organoid cultures to provide preclinical testing platforms for precision cancer immunotherapy.

Cite

CITATION STYLE

APA

Grönholm, M., Feodoroff, M., Antignani, G., Martins, B., Hamdan, F., & Cerullo, V. (2021, June 1). Patient-derived organoids for precision cancer immunotherapy. Cancer Research. American Association for Cancer Research Inc. https://doi.org/10.1158/0008-5472.CAN-20-4026

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free